175 related articles for article (PubMed ID: 9351491)
1. Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels.
Knable MB; Heinz A; Raedler T; Weinberger DR
Psychiatry Res; 1997 Sep; 75(2):91-101. PubMed ID: 9351491
[TBL] [Abstract][Full Text] [Related]
2. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
[TBL] [Abstract][Full Text] [Related]
3. [123I]IBZM SPECT in patients treated with typical and atypical neuroleptics: relationship to drug plasma levels and extrapyramidal side effects.
Schlösser R; Schlegel S; Hiemke C; Nickel O; Bockisch A; Rao ML; Hahn K
Psychiatry Res; 1997 Sep; 75(2):103-14. PubMed ID: 9351492
[TBL] [Abstract][Full Text] [Related]
4. Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia.
Lavalaye J; Linszen DH; Booij J; Reneman L; Gersons BP; van Royen EA
Psychiatry Res; 1999 Nov; 92(1):33-44. PubMed ID: 10688158
[TBL] [Abstract][Full Text] [Related]
5. Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome.
Jauss M; Krack P; Franz M; Klett R; Bauer R; Gallhofer B; Dorndorf W
Mov Disord; 1996 Nov; 11(6):726-8. PubMed ID: 8914102
[TBL] [Abstract][Full Text] [Related]
6. Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone.
Küfferle B; Brücke T; Topitz-Schratzberger A; Tauscher J; Gössler R; Vesely C; Asenbaum S; Podreka I; Kasper S
Psychiatry Res; 1996 Nov; 68(1):23-30. PubMed ID: 9027930
[TBL] [Abstract][Full Text] [Related]
7. Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.
Bernardo M; Parellada E; Lomeña F; Catafau AM; Font M; Gómez JC; López-Carrero C; Gutiérrez F; Pavía J; Salamero M
Psychiatry Res; 2001 Aug; 107(2):87-97. PubMed ID: 11530275
[TBL] [Abstract][Full Text] [Related]
8. Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123I-IBZM SPECT study.
Kasper S; Tauscher J; Küfferle B; Barnas C; Hesselmann B; Asenbaum S; Podreka I; Brücke T
Psychopharmacology (Berl); 1998 Apr; 136(4):367-73. PubMed ID: 9600582
[TBL] [Abstract][Full Text] [Related]
9. Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol.
Corripio I; Catafau AM; Perez V; Puigdemont D; Mena E; Aguilar Y; Carrió I; Alvarez E
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):91-6. PubMed ID: 15610950
[TBL] [Abstract][Full Text] [Related]
10. In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.
Dresel S; Mager T; Rossmüller B; Meisenzahl E; Hahn K; Möller HJ; Tatsch K
Eur J Nucl Med; 1999 Aug; 26(8):862-8. PubMed ID: 10436199
[TBL] [Abstract][Full Text] [Related]
11. Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol.
Tauscher J; Küfferle B; Asenbaum S; Tauscher-Wisniewski S; Kasper S
Psychopharmacology (Berl); 2002 Jun; 162(1):42-9. PubMed ID: 12107616
[TBL] [Abstract][Full Text] [Related]
12. Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride--an 123I-IBZM single photon emission tomography (SPET) study.
Busatto GF; Pilowsky LS; Costa DC; Ell PJ; Verhoeff NP; Kerwin RW
Psychopharmacology (Berl); 1995 Jan; 117(1):55-61. PubMed ID: 7536945
[TBL] [Abstract][Full Text] [Related]
13. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography.
Schotte A; Janssen PF; Megens AA; Leysen JE
Brain Res; 1993 Dec; 631(2):191-202. PubMed ID: 7510574
[TBL] [Abstract][Full Text] [Related]
14. D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects.
Scherer J; Tatsch K; Schwarz J; Oertel WH; Konjarczyk M; Albus M
Acta Psychiatr Scand; 1994 Oct; 90(4):266-8. PubMed ID: 7831996
[TBL] [Abstract][Full Text] [Related]
15. In vivo dopamine-D2 and serotonin-5-HT2 receptor binding study of risperidone and haloperidol.
Sumiyoshi T; Kido H; Sakamoto H; Urasaki K; Suzuki K; Yamaguchi N; Mori H; Shiba K; Yokogawa K
Pharmacol Biochem Behav; 1994 Mar; 47(3):553-7. PubMed ID: 7516078
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
Tada M; Shirakawa K; Matsuoka N; Mutoh S
Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
[TBL] [Abstract][Full Text] [Related]
17. In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol.
Tauscher J; Küfferle B; Asenbaum S; Fischer P; Pezawas L; Barnas C; Tauscher-Wisniewski S; Brücke T; Kasper S
Psychopharmacology (Berl); 1999 Jan; 141(2):175-81. PubMed ID: 9952042
[TBL] [Abstract][Full Text] [Related]
18. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
[TBL] [Abstract][Full Text] [Related]
19. Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study.
Bressan RA; Erlandsson K; Jones HM; Mulligan RS; Ell PJ; Pilowsky LS
J Clin Psychopharmacol; 2003 Feb; 23(1):5-14. PubMed ID: 12544369
[TBL] [Abstract][Full Text] [Related]
20. IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol.
Küfferle B; Tauscher J; Asenbaum S; Vesely C; Podreka I; Brücke T; Kasper S
Psychopharmacology (Berl); 1997 Oct; 133(4):323-8. PubMed ID: 9372530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
